Fishing around for the undervalued.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
#2 on breakout boards, future bright here IMO
$BLEG
Great candidate .01+ 2024.
$RSPI
$BLEG Nice accumulation. Would be nice for a float lock with micro SS
Company building, doing all the right things moving forward.
$BLEG
My shares locked over .01+
$BLEG
$BLEG Setting up for golden cross ahead IMO. 50dma at .0021, 200dma at .0027. Trading clean
$BLEG golden cross setting up
$BLEG 24 million volume
GM all, very thin on ask
$BLEG news: Branded Legacy, Inc. Reduces Debt by 1.5 Million
Branded Legacy, Inc.(OTC.PK: BLEG) Takes Bold Step in Financial Management: Eliminates $1.5 Million in Debt and Safeguards Against Conversions
https://ih.advfn.com/stock-market/USOTC/branded-legacy-pk-BLEG/stock-news/93138486/branded-legacy-inc-reduces-debt-by-1-5-million
$BLEG news: Branded Legacy, Inc. Reduces Debt by 1.5 Million
Branded Legacy, Inc.(OTC.PK: BLEG) Takes Bold Step in Financial Management: Eliminates $1.5 Million in Debt and Safeguards Against Conversions
https://ih.advfn.com/stock-market/USOTC/branded-legacy-pk-BLEG/stock-news/93138486/branded-legacy-inc-reduces-debt-by-1-5-million
$BLEG news: Branded Legacy, Inc. Reduces Debt by 1.5 Million
Jan 25, 2024 | News
https://brandedlegacy.com/branded-legacy-inc-reduces-debt-by-1-5-million/
$RSPI website, read releases: https://respirerx.com/
$BLEG SS now in great position for future growth. Step 1 accomplished.
$RSPI website in the news
Higher highs, higher lows on daily chart. Longs to be rewarded here IMO .0191 52 week high, looking forward to results from trials.
$RSPI
$BLEG delivering on share reduction: https://www.otcmarkets.com/stock/BLEG/security
Authorized Shares
900,000,000
01/22/2024
Outstanding Shares
512,913,066
01/11/2024
Restricted
112,847,209
01/11/2024
Unrestricted
400,065,857
01/11/2024
Held at DTC
400,042,389
01/11/2024
Float
400,065,857
12/14/2022
$BLEG delivering on share reduction: https://www.otcmarkets.com/stock/BLEG/security
Authorized Shares
900,000,000
01/22/2024
Outstanding Shares
512,913,066
01/11/2024
Restricted
112,847,209
01/11/2024
Unrestricted
400,065,857
01/11/2024
Held at DTC
400,042,389
01/11/2024
Float
400,065,857
12/14/2022
$RSPI RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
RespireRx Pharmaceuticals Inc. (RSPI) reports successful suppression of epileptiform activity in a 19-year-old patient with pharmaco-resistant epilepsy using KRM-II-81, a novel GABAkine. The findings, published in Heliyon, Cell Press's peer-reviewed journal, suggest potential success in reducing seizure burden in pharmaco-resistant patients.
Positive
Successful suppression of epileptiform activity in a 19-year-old patient with pharmaco-resistant epilepsy
Publication of findings in Heliyon, Cell Press's peer-reviewed journal
Positive translational support for the potential of KRM-II-81 in reducing seizure burden in pharmaco-resistant patients
Negative
None.
01/04/2024 - 08:45 AM
Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the publication of a case report in Heliyon, Cell Press’s peer-reviewed journal (available at https://www.cell.com/heliyon/pdf/S2405-8440(23)10960-1.pdf) involving a 19-year old patient with pharmaco-resistant epilepsy. As is often the case with such patients, tolerance developed to the standard anti-epileptic treatments, rendering them ineffective, and the patient required a craniotomy in order to remove the brain tissue responsible for the seizure generation. One year after surgery, the patient remains seizure free, but remains on medication.
Cortical brain tissue surgically resected from the patient exhibited epileptiform bursting with microelectrode recordings. When KRM–II–81, one of our lead GABAkines, was added the incubation fluid, the epileptiform activity in the excised brain tissue was fully suppressed. KRM–II–81 is a novel a2/3 subtype preferring GABAA receptor potentiator that previously demonstrated anti-epileptic efficacy in multiple animal models of epilepsy as well as a lack of drug tolerance and reduced undesirable side-effects. These findings add translational support to the proposition that KRM–II–81 might reduce seizure burden in pharmaco-resistant patients.
Jodi L. Smith, PhD, MD, FAANS, Director, Pediatric Neurosurgery at Peyton Manning Children’s Hospital at Ascension St. Vincent Medical in Indianapolis, IN led this research effort and is quoted as saying, “I am happy to report that a year after the surgery the patient is seizure-free but remains on seizure medication. Although our research team has observed suppression of activity previously in cortical tissue from epileptic patients, we have now observed recurrent epileptiform bursting in this patient’s tissue. KRM-II-81 fully suppressed the epileptiform bursting, which returned when KRM-II-81 was removed from the incubation medium. We feel that this observation is an impressive indicator for success in translation to patient treatment for this compound.”
The manuscript’s corresponding author Rok Cerne, MD, PhD, Senior Research Fellow with RepireRx, said that “the bursting activity across a neural network is a unique signature of epilepsy that we were able to observe in the cortical tissue from this patient. Prior to surgery, this 19-year-old patient suffered from seizures in the presence of multiple standard anti-seizure medications. The complete abolishment of these epileptic bursts by our GABAkine is one of most impressive demonstrations we have made to date with KRM-II-81. The data are highly encouraging for us to continue with IND enabling animal studies conducted in collaboration with the National Institutes of Health and to move into the clinic with KRM-II-81.”
Epilepsy is a highly prevalent, life-disrupting and life-threatening neurological disorder for which about 30% of the millions of patients worldwide do not respond to treatment. It is for this reason that research efforts such as ours continue with the search for safe and more effective antiseizure medications. The present research finding, along with a large data base of preclinical studies, predicts that KRM-II-81 will be effective in those patients not treated successfully with standard of care medicines. The additional possibility of a non-sedating and non-addicting profile along with the lack of tolerance development adds to our confidence in moving KRM-II-81 forward into patient clinical trials.
About RespireRx Group
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units (“RespireRx Group”) are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors.
$BLEG multi-state processing licenses, a compounding pharmacy license, advanced equipment, and a fleet of licensed and permitted vehicles. They are gearing up here for revenues.
Exactly.
Company is growing, and with share reduction easier to move forward
$BLEG
$RSPI accumulation building pressure for breakout
$BLEG .01+ could be achievable with a little patience on this reduction of shares
$BLEG 1/23/24 CEO letter:
https://brandedlegacy.com/ceo-letter-january-2024/
Headed towards a golden cross too.
$BLEG
$RSPI Higher highs, higher lows on the daily chart, looking good
$BLEG News: Branded Legacy, Inc. ($BLEG) Announces Reduction in Authorized Share Count to 900M
January 23 2024 - 08:30AM
InvestorsHub NewsWire
https://ih.advfn.com/stock-market/USOTC/branded-legacy-pk-BLEG/stock-news/93113773/branded-legacy-inc-bleg-announces-reduction-in
$BLEG News: Branded Legacy, Inc. ($BLEG) Announces Reduction in Authorized Share Count to 900M
January 23 2024 - 08:30AM
InvestorsHub NewsWire
https://ih.advfn.com/stock-market/USOTC/branded-legacy-pk-BLEG/stock-news/93113773/branded-legacy-inc-bleg-announces-reduction-in
$BLEG News: Branded Legacy, Inc. ($BLEG) Announces Reduction in Authorized Share Count to 900M
https://ih.advfn.com/stock-market/USOTC/branded-legacy-pk-BLEG/stock-news/93113773/branded-legacy-inc-bleg-announces-reduction-in
$RSPI 26-11 accumulation today so far
$RSPI .0018 being accumulated
$RSPI Experience added to the team: https://doctor.webmd.com/doctor/dariusz-nasiek-8a818d3a-3c7b-4a66-b554-eb3053e9da1b-overview
$RSPI 52 week high .0191
Nice accumulation in this range.
$BLEG CEO active on X today:
I've learned my lesson about public statements before the receipts come in.
— Dave Oswald (@Dave_Oswald_CEO) January 19, 2024
When our next news drops everything will already be in place, and there should be no complaints from anyone $BLEG
RSPI Looking forward to phase III results: